Outcome of 2 Simplification Strategies for the Treatment of Human Immunodeficiency Virus Type 1 Infection (original) (raw)
The Danish Protease Inhibitor Study: A Randomized Study Comparing the Virological Efficacy of 3 Protease Inhibitor–Containing Regimens for the Treatment of Human Immunodeficiency Virus Type 1 Infection
J. Gerstoft
The Journal of Infectious Diseases, 2000
View PDFchevron_right
The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection
Alejandro Arenas-Pinto
Health technology assessment (Winchester, England), 2016
View PDFchevron_right
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
Alejandro Arenas-Pinto
The Lancet HIV, 2015
View PDFchevron_right
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy in the PIVOT trial
Alejandro Arenas-Pinto
AIDS (London, England), 2016
View PDFchevron_right
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
Nathan Gonzalez
Aids, 2003
View PDFchevron_right
Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
Antonio Antela
AIDS, 1998
View PDFchevron_right
Simplification Therapy with Once‐Daily Emtricitabine, Didanosine, and Efavirenz in HIV‐1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial
Bertrand Dupont
The Journal of Infectious Diseases, 2005
View PDFchevron_right
Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected Persons
Remko Van Leeuwen
The Journal of Infectious Diseases, 1999
View PDFchevron_right
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
S. Ubolyam
Journal of Antimicrobial Chemotherapy, 2008
View PDFchevron_right
Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome
Margaret Chesney
The Journal of Infectious Diseases, 1999
View PDFchevron_right
Limitations of a Simplification Antiretroviral Strategy for HIV-Infected Patients with Decreasing Adherence to a Protease Inhibitor Regimen
Fernando Dronda
HIV Clinical Trials, 2006
View PDFchevron_right
Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
S. Cuellar
AIDS Research and Therapy, 2013
View PDFchevron_right
A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
David Dalmau
Revista clínica española, 2007
View PDFchevron_right
Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART
Paola Meraviglia
Journal of Antimicrobial Chemotherapy, 2005
View PDFchevron_right
Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression
luis cruz
Clinical Infectious Diseases, 2002
View PDFchevron_right
Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)
Clotilde Allavena
The Journal of Infectious Diseases, 2002
View PDFchevron_right
Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study
Núria Pérez
PLoS ONE, 2014
View PDFchevron_right
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
Eva Van Den Eynde
Journal of Antimicrobial Chemotherapy, 2012
View PDFchevron_right
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
Robert DiCenzo
AIDS, 2009
View PDFchevron_right
Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV1-infected patients
Milos Opravil
Aids, 2003
View PDFchevron_right
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens
Thomas Campbell
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014
View PDFchevron_right
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and …
Margaret Chesney
Journal of Infectious …, 1999
View PDFchevron_right
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Gary Pakes
BMC infectious diseases, 2005
View PDFchevron_right
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Ellen Koenig
The lancet. HIV, 2018
View PDFchevron_right
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
Cristina Cortés
New England Journal of Medicine, 2003
View PDFchevron_right